598 related articles for article (PubMed ID: 27019997)
1. Immune checkpoint inhibitors in lung cancer: past, present and future.
Seetharamu N; Budman DR; Sullivan KM
Future Oncol; 2016 May; 12(9):1151-63. PubMed ID: 27019997
[TBL] [Abstract][Full Text] [Related]
2. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
Garon EB
Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
[TBL] [Abstract][Full Text] [Related]
3. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors.
Langer CJ
Am J Clin Oncol; 2015 Aug; 38(4):422-30. PubMed ID: 24685885
[TBL] [Abstract][Full Text] [Related]
4. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
Tanvetyanon T; Gray JE; Antonia SJ
Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
[TBL] [Abstract][Full Text] [Related]
5. Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer.
Lim SW; Ahn MJ
Korean J Intern Med; 2019 Jan; 34(1):50-59. PubMed ID: 30612418
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint therapy for non-small-cell lung cancer: an update.
Xia B; Herbst RS
Immunotherapy; 2016; 8(3):279-98. PubMed ID: 26860624
[TBL] [Abstract][Full Text] [Related]
7. Anti-PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy.
Valecha GK; Vennepureddy A; Ibrahim U; Safa F; Samra B; Atallah JP
Expert Rev Anticancer Ther; 2017 Jan; 17(1):47-59. PubMed ID: 27841044
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Herzberg B; Campo MJ; Gainor JF
Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
[TBL] [Abstract][Full Text] [Related]
9. Targeting immune checkpoints in non small cell lung cancer.
Bianco A; Malapelle U; Rocco D; Perrotta F; Mazzarella G
Curr Opin Pharmacol; 2018 Jun; 40():46-50. PubMed ID: 29525401
[TBL] [Abstract][Full Text] [Related]
10. PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer.
Bagley SJ; Bauml JM; Langer CJ
Clin Adv Hematol Oncol; 2015 Oct; 13(10):676-83. PubMed ID: 27058572
[TBL] [Abstract][Full Text] [Related]
11. Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer.
Wu Z; Man S; Sun R; Li Z; Wu Y; Zuo D
Int Immunopharmacol; 2020 Aug; 85():106613. PubMed ID: 32450531
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms.
Monteiro ID; Califano R; Mountzios G; de Mello RA
Future Oncol; 2016 Feb; 12(4):551-64. PubMed ID: 26776915
[TBL] [Abstract][Full Text] [Related]
13. Advances in the Treatment of Non-small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab.
Leventakos K; Mansfield AS
BioDrugs; 2016 Oct; 30(5):397-405. PubMed ID: 27411930
[TBL] [Abstract][Full Text] [Related]
14. Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer.
Rossi E; Sgambato A; De Chiara G; Casaluce F; Losanno T; Sacco PC; Santabarbara G; Gridelli C
Expert Rev Clin Pharmacol; 2016; 9(3):419-28. PubMed ID: 26681547
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
Farina MS; Lundgren KT; Bellmunt J
Drugs; 2017 Jul; 77(10):1077-1089. PubMed ID: 28493171
[TBL] [Abstract][Full Text] [Related]
16. [Immune Checkpoint Therapy for Non-Small-Cell Lung Cancer].
Miyauchi E; Inoue A
Gan To Kagaku Ryoho; 2016 Jun; 43(6):666-71. PubMed ID: 27306803
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab plus ipilimumab in non-small-cell lung cancer.
Reck M; Borghaei H; O'Byrne KJ
Future Oncol; 2019 Jul; 15(19):2287-2302. PubMed ID: 31066582
[TBL] [Abstract][Full Text] [Related]
18. New Immunotherapy and Lung Cancer.
Sánchez de Cos Escuín J
Arch Bronconeumol; 2017 Dec; 53(12):682-687. PubMed ID: 28823733
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy and safety of PD-1/PD-L1 immunotherapies for non-small cell lung cancer: a network meta-analysis.
Wang DD; Shaver LG; Shi FY; Wei JJ; Qin TZ; Wang SZ; Kong YJ
Eur Rev Med Pharmacol Sci; 2021 Apr; 25(7):2866-2884. PubMed ID: 33877652
[TBL] [Abstract][Full Text] [Related]
20. The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly.
Sgambato A; Casaluce F; Gridelli C
Expert Opin Biol Ther; 2017 May; 17(5):565-571. PubMed ID: 28276698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
